Skip to main content

Table 1 Baseline Characteristics of Patients in the Study

From: The impact of serum lipids on risk for microangiopathy in patients with type 2 diabetes mellitus

Characteristics Patients N =72,267
n %
Female 35,192 48.70
Age at index (years), mean ± SD 49.91 ± 9.44
Geographic Region
West 21,098 29.19
South 19,727 27.30
Northeast 15,756 21.80
Midwest 11,231 15.54
Unknown 4,455 6.16
Health Plan Type
HMO 35,017 48.46
PPO 31,556 43.67
POS 2,347 3.29
FFS 65 0.09
Other 3,255 4.50
Index year
2005-06 21,929 30.34
2007-08 30,767 42.57
2009-10 19,571 27.08
Physician specialty
General family practice 22,927 31.34
Internal medicine 17,817 24.65
Endocrinology 1,963 2.72
Cardiology 800 1.11
Others/unknown 28,760 39.80
Lipid Subfraction 1
LDL-C 115.71 ±35.65
Goal attainment2 23,858 64.28
HDL-C 47.28 ±13.90
Goal attainment 36,171 50.05
TG 186.69 ±176.52
Goal attainment 43,230 59.82
nonHDL-C 150.61 ±43.53
Goal attainment2 21,081 56.79
Comorbidities
Ischemic heart disease 66,428 91.92
Hypertension 42,605 58.95
Obesity 4,912 6.80
Depression 3,947 5.46
Heart failure 2,511 3.47
Cerebrovascular disease 2,023 2.80
Metabolic syndrome 1,940 2.68
Liver disease 1,932 2.67
Peripheral vascular disease 1,554 2.15
Renal disease3 394 0.55
Schizophrenia 68 0.09
DCI score, mean ± SD 0.34 ±0.9
Medication Use 4
Antihypertensive Medications 14,387 19.91
ACE Inhibitors 10,444 14.45
ARBs 4,515 6.25
Lipid Altering Therapies
Statin
Low Potency 2,422 3.35
Medium Potency 9,840 13.62
High Potency 12,851 17.78
Niacin 1,668 2.31
Ezetimibe 3,827 5.30
Fibrate   
Fenofibrate 3,211 4.44
Gemfibrozil 1,254 1.74
Days of Study Follow-up 5 , mean ± SD 652.58 ±484.18
  1. 1 The lipid panel values are derived from the most recent lab assessment results prior to the index date.
  2. 2 For LDL-C and non-HDL-C: Goal attainment based on subsample of 37,118 patients since 35,149 patients had no discernible risk at baseline.
  3. 3 Pre-index renal disease includes acute renal failure, hypertensive kidney disease, and glomerulonephritis.
  4. 4 n and % of patients with any fill for medication of interest.
  5. 5 Number of days from index date to end of study follow up (defined as the end of earliest occurrence of event of interest, death, patient becoming 65 years or older, end of health plan eligibility, or 6/30/2010).
  6. LDL-C: low-density lipoprotein cholesterol; HDL-C: high-density lipoprotein cholesterol; TG: triglycerides; ACE: angiotensin-converting enzyme; ARB: angiotensin receptor blockers; HMO: health maintenance organization; PPO: patient preferred organization; POS: point of service; FFS: fee for service.